CLINICAL DATA
The ULTIMA Trial
SEATTLE II Trial
OPTALYSE PE
Nykamp-Laurich
Hi-PEITHO Trial
KNOCOUT PE Study
CLINICAL DATA
The ULTIMA Trial
SEATTLE II Trial
OPTALYSE PE
Nykamp-Laurich
Hi-PEITHO Trial
KNOCOUT PE Study

 
Vascular Surgery / Venous Thromboembolism / Pulmonary Embolism / Clinical Data / KNOCOUT PE

 

The Largest Data Set in the Interventional Treatment of PE Just Got Bigger

 

KNOCOUT PE
Prospective Cohort: 3-Month Data

 

 

Study Objective

To understand the impact of the EKOS™ Endovascular System low-dose, short treatment duration OPTALYSE PE study on various ultrasound-accelerated thrombolysis (USAT) protocols being used as the standard of care in the treatment of acute pulmonary embolism and associated long-term outcomes including quality of life outcomes.

Blue circle with illustration of lines and dots depicting strength of data
489 patients in the prospective cohort
Blue circle with illustration of brain. Safety 0ICH
Zero intracerebral hemorrhagic events
RV Reduction LV Efficacy 23%
23% RV / LV reduction post-procedure
Download the Data Summary
KNOCOUT PE

Importance:

With 489 patients, the prospective KNOCOUT cohort represents the largest prospective body of evidence in the interventional PE space to-date. The registry included a wide range of patients with intermediate-high and high-risk PE, making it an accurate representation of patients with PE treated with EKOS every day. In addition, KNOCOUT captures the largest breadth of contemporary clinical practices with 83 centers enrolled across the United States and Europe between 2018 and 2020.

Take-away:

Results from KNOCOUT PE reflect contemporary clinical practice and demonstrated effective treatment of PE with EKOS with lower r-tPA dose and shorter infusion duration, and low major hemorrhagic complications and zero intracerebral hemorrhagic events.

Top